The war on Hydroxychloroquine can be traced back to Gilead, the drug maker looking to profit big from Remdesivir | WHAT REALLY HAPPENED

The war on Hydroxychloroquine can be traced back to Gilead, the drug maker looking to profit big from Remdesivir

It was beyond strange when the major media networks began to attack a pharmaceutical, especially in the middle of a pandemic. When did the major media networks ever criticize a drug? It turns out that controversial pharmaceutical is a cheap medicine that helps human cells uptake zinc so their immune system can recover from coronavirus infections.

Dr. Didier Raoult of France was using something as simple and cheap as hydroxychloroquine (HCQ) in combination with zinc and an antibiotic to successfully treat coronavirus patients. The news of Raoult’s success spread like wildfire, and U.S. President Donald Trump ultimately promoted the treatment, which acts as both a prophylactic and a therapeutic.

But it doesn’t matter how many doctors successfully treat coronavirus patients using HCQ and zinc. It doesn’t matter what people do in the home to help their immune system through the infection. What matters is drug company profits.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA